fbpx

Federal Circuit Says Amgen’s Repatha® Patent Claims Require ‘Undue Experimentation’ to PracticeBy: Eileen McDermotton February 13, 2021 at 5:15 pm Publication: IPWatchdog.com | Patents & Patent Law

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Thursday upheld the District of Delaware’s grant of judgment as a matter of law (JMOL) that Amgen’s patent claims covering its Repatha cholesterol treatment were invalid for lack of enablement. The court found that Amgen’s composition  Read More>>

Categories   Courts, District Courts, Federal Circuit, IP News, IPWatchdog Articles, Litigation, Patents, USPTO, amgen, CAFC, enablement, intellectual property, patent, Patent Litigation, patent prosecution, Patentability, patentability requirements, patents, Repatha, specification

YouTube
LinkedIn
LinkedIn
Share